Article
Biochemistry & Molecular Biology
Jeon Hwang-Bo, Karpagam Veerappan, Hyunhye Moon, Tae-Hoon Lee, Kang-Woon Lee, Junhyung Park, Hoyong Chung
Summary: Atopic dermatitis is a chronic inflammatory skin disease that requires continuous treatment. This study found that a peptide called parnassin can alleviate atopic dermatitis by modulating the immune system, with fewer side effects. It could be a potential candidate drug for the treatment of atopic dermatitis.
Review
Dermatology
Maria Bracho-Borro, Paulina Ailed Franco-Ruiz, Mario Magana
Summary: This paper provides a detailed description of the indications, mechanism of action, interactions, adverse effects, monitoring, and precautions in special populations for the use of azathioprine in the treatment of AD. It helps dermatologists prescribe this drug safely to patients who require it.
DERMATOLOGIC THERAPY
(2022)
Review
Biochemistry & Molecular Biology
Gaku Tsuji, Kazuhiko Yamamura, Koji Kawamura, Makiko Kido-Nakahara, Takamichi Ito, Takeshi Nakahara
Summary: Atopic dermatitis (AD) is a chronic inflammatory skin disease with a complex pathogenesis involving skin barrier dysfunction, type II immune response, and pruritus. Advances in understanding the immunological mechanisms of AD have identified multiple novel therapeutic targets. New biologic agents targeting various cytokines and pathways are being developed for systemic and topical therapy, including JAK inhibitors, histamine H4 receptor antagonists, and microbiome modulation. This review provides insights into the current and future directions of novel therapies for AD and highlights their mechanisms of action and efficacy, supporting the advancement of precision medicine in the treatment of AD.
Article
Biochemistry & Molecular Biology
Dongwoo Lee, Jeon Hwang-Bo, Karpagam Veerappan, Hyunhye Moon, Junhyung Park, Hoyong Chung
Summary: This study confirms the anti-inflammatory effect of TPS240 in atopic dermatitis using animal models and cell experiments. TPS240 not only reduces skin lesions and symptoms, but also does not cause side effects observed in existing treatments. It shows potential as a candidate drug for the prevention and treatment of atopic dermatitis.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Pharmacology & Pharmacy
Lorenzo Maria Pinto, Andrea Chiricozzi, Laura Calabrese, Maria Mannino, Ketty Peris
Summary: Topical agents currently used for atopic dermatitis treatment may be effective for mild or mild-moderate cases, but more complex or unresponsive cases often require additional systemic therapies. The most commonly used compounds are topical corticosteroids and calcineurin inhibitors, although they may have side effects, low response rates, and poor patient compliance. Therefore, the development of new drugs with higher efficacy and safety is necessary.
Review
Cell Biology
Masanori Fujii
Summary: Ceramide abnormalities in atopic dermatitis (AD) are believed to be part of the disease's pathogenesis, with the involvement of Th2 and Th1 cytokines. Emollients rich in ceramides have been approved as adjunctive barrier repair agents for AD.
Review
Dermatology
Maddalena Napolitano, Gabriella Fabbrocini, Fabrizio Martora, Lucia Genco, Matteo Noto, Cataldo Patruno
Summary: Atopic dermatitis (AD) is a chronic inflammatory skin condition that causes itching and has a significant psychosocial impact on patients and their relatives. It presents with various clinical phenotypes, with varying severity and course. Diagnosis relies on experienced dermatologists, and misdiagnosis and delayed treatment can have negative effects on the patient's health.
DERMATOLOGIC THERAPY
(2022)
Article
Plant Sciences
Dian -Dong Hou, Ya-Jing Gu, De-Cheng Wang, Yuan Niu, Zi-Ran Xu, Zhuo-Qun Jin, Xin-Xin Wang, Si-Jia Li
Summary: The study investigated the therapeutic effects of myricetin on atopic dermatitis. The results showed that myricetin has anti-inflammatory and antiallergic effects, and can alleviate the symptoms of atopic dermatitis. Additionally, myricetin can regulate the expression of various cytokines and exert its therapeutic effects by blocking signal pathways.
Article
Chemistry, Multidisciplinary
Ye Eun Kim, Seung Woo Choi, Min Kyung Kim, Thanh Loc Nguyen, Jaeyun Kim
Summary: Atopic dermatitis (AD) is a chronic inflammatory disease associated with immune imbalances in the skin. High oxidative stress is implicated in AD pathogenesis. A therapeutic hydrogel patch embedded with ROS-scavenging nanoparticles shows promising results in reducing oxidative stress and improving AD symptoms in mouse models.
Article
Immunology
Yiteng Lu, Ye Sun, Yong Peng, Xiaoqiang Zhao, Danjie Wang, Tongtong Zhang, Fang Qian, Jun Wang
Summary: The role of Gasdermin D (GSDMD) in atopic dermatitis (AD) was investigated. Through analysis of gene expression data and mouse experiments, it was found that GSDMD deletion and inhibition can alleviate symptoms of AD, such as reduced skin thickness, scarring, and scratching behavior. Furthermore, GSDMD deletion and inhibition also resulted in reduced infiltration of inflammatory cells, decreased epidermal thickness, and lower levels of IL-18 and IL-18.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Immunology
Wirawan Adikusuma, Lalu Muhammad Irham, Wan-Hsuan Chou, Henry Sung-Ching Wong, Eko Mugiyanto, Jafit Ting, Dyah Aryani Perwitasari, Wei-Pin Chang, Wei-Chiao Chang
Summary: This study aimed to discover potential treatments for Atopic Dermatitis (AD) by integrating gene networking and genomic information. The research identified 27 biological AD risk genes mapped to 76 drug target genes, with 25 drug target genes overlapping with 53 drugs. The study also found several potential drugs for AD, including filgotinub and fedratinib targeting gene JAK1, as well as four monoclonal antibody drugs deemed promising for AD repurposing.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Engineering, Biomedical
Mingyu Jang, Bo Mi Kang, Huisuk Yang, Jungyoon Ohn, Ohsang Kwon, Hyungil Jung
Summary: Dissolving microneedles (DMN) with therapeutic molecules have been developed to enhance transdermal drug delivery efficiency, particularly for treating skin inflammatory diseases like atopic dermatitis (AD). High-dose TA-DMN is presented as a potential candidate for the treatment of skin inflammatory diseases.
ADVANCED HEALTHCARE MATERIALS
(2021)
Article
Pharmacology & Pharmacy
Noa Ben David, Yuval Richtman, Adi Gross, Ruba Ibrahim, Abraham Nyska, Yuval Ramot, Boaz Mizrahi
Summary: Atopic dermatitis is a chronic inflammatory skin disease caused by immune dysregulation. This study developed a new delivery system for AD treatment using dissolvable microneedles containing dexamethasone. The microneedles showed good structure, fast drug release, appropriate mechanical strength, and low cytotoxicity. In vivo testing on mice showed significant clinical improvements. Microneedle devices loaded with dexamethasone have potential as a treatment for AD and other skin conditions.
Article
Dermatology
K. Thormann, H. Aubert, S. Barbarot, A. Britsch-Yilmaz, P. Chernyshov, M. Deleuran, M. El-Hachem, J. Groot, A. Heratizadeh, F. Raymakers, J. F. Stalder, A. Wollenberg, D. Simon
Summary: Therapeutic patient education (TPE) is an effective approach to improve self-management and adherence in chronic skin diseases like atopic dermatitis (AD). Trained dermatology nurses play a crucial role in delivering TPE, resulting in positive effects on disease management and health-related outcomes for AD patients. The analysis and recommendations in this position paper aim to enhance the efficacy of TPE programs and identify specific roles for healthcare professionals in the care of AD patients.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Article
Engineering, Biomedical
Subin Choi, Junghyeon Ko, Su-Bin Park, Joo-Young Kim, Jung-Hwa Ha, Sangho Roh, Young-Hyeon An, Nathaniel S. Hwang
Summary: A transdermal delivery system of a polyphenol mixture (PM) has been developed to treat atopic dermatitis (AD) using double emulsion technology. The PM has been optimized in terms of the molar ratio of each polyphenol, and the water-in-oil-in-water double emulsion (W/O/W) formulation has shown enhanced stability and anti-degranulation effects compared to the oil-in-water emulsion (O/W). In in vivo experiments, the PM-encapsulated W/O/W formulation has demonstrated the most effective reduction of AD symptoms.
ADVANCED HEALTHCARE MATERIALS
(2023)